Executive Summary

**Purpose:** Ensure appropriate utilization and control of Selzentry® (maraviroc)

**Why Issue Selected:** Selzentry® (maraviroc) is a CCR5 (C-C chemokine receptor type 5) co-receptor antagonist indicated for the treatment of only CCR5-tropic HIV-1 infection with other antiretroviral agents. In 2016, Selzentry received FDA approval to expand its indication to include treatment of pediatric patients 2 years of age and older. Selzentry works by selectively binding to the human chemokine receptor CCR5 present on the cell membrane and preventing the interaction of HIV-1 gp 120 and CCR5; this interaction is necessary for CCR5-tropic HIV-1 to enter cells. Selzentry is not recommended in patients with CXCR4-tropic or dual/mixed HIV-1 as it is ineffective in these cases. The Trofile® test is used to determine if a patient's virus is suitable for a CCR5 co-receptor antagonist therapy; the results of the Trofile test will determine if Selzentry is an appropriate treatment choice for the patient. Also, as compared to treatment with Sustiva® (efavirenz), treatment-naïve adults treated with Selzentry experienced more virologic failure and lamivudine resistance; therefore, Selzentry is not recommended for use in treatment-naïve patients. Due to the specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Selzentry.

**Program-Specific Information:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Date Range FFS 10-01-2020 to 9-30-2021</th>
<th>Claims</th>
<th>Spend</th>
<th>Avg Spend per Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>SELZENTRY 25 MG TABLET</td>
<td></td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SELZENTRY 75 MG TABLET</td>
<td></td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SELZENTRY 150 MG TABLET</td>
<td></td>
<td>21</td>
<td>$31,922.27</td>
<td>$1,520.11</td>
</tr>
<tr>
<td>SELZENTRY 300 MG TABLET</td>
<td></td>
<td>25</td>
<td>$29,157.16</td>
<td>$1,166.29</td>
</tr>
<tr>
<td>SELZENTRY 20 MG/ML SOLN</td>
<td></td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Type of Criteria:**
- ☒ Increased risk of ADE
- ☐ Preferred Drug List
- ☐ Appropriate Indications
- ☒ Clinical Edit
- ☒ Databases + Prescriber-Supplied

Setting & Population
Drug class for review: Selzentry® (maraviroc)
Age range: All appropriate MO HealthNet participants aged 2 years and older

Approval Criteria

- Participant is aged ≥ 2 years AND
- Participant is HIV infected AND
- Participant has history of positive viral tropism for CCR5-tropic HIV AND
- Participant is not treatment naïve (participant has been on antiretroviral medication before) AND
- Participant is currently on additional antiretroviral medication besides Selzentry (maraviroc)

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results: X  Progress Notes: X  MedWatch Form:  Other:

Disposition of Edit

Denial: Exception code “0682” (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

References